Abbott Laboratories (NYSE:ABT) was the recipient of unusually large options trading on Wednesday. Traders acquired 115,175 call options on the stock. This is an increase of 4,299% compared to the typical volume of 2,618 call options.

Several brokerages have recently commented on ABT. BMO Capital Markets restated a “market perform” rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Barclays raised their target price on Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, September 28th. Bank of America restated a “buy” rating and issued a $60.00 target price (up from $56.00) on shares of Abbott Laboratories in a research note on Wednesday, October 4th. ValuEngine downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Stifel Nicolaus raised their target price on Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, October 19th. Six analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $60.24.

Abbott Laboratories (ABT) opened at $58.84 on Friday. The stock has a market capitalization of $102,420.00, a PE ratio of 48.63, a price-to-earnings-growth ratio of 1.88 and a beta of 1.55. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. Abbott Laboratories has a 12 month low of $39.25 and a 12 month high of $59.60.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. The business had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The company’s quarterly revenue was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.59 EPS. equities research analysts expect that Abbott Laboratories will post 2.5 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a dividend of $0.28 per share. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $1.12 dividend on an annualized basis and a yield of 1.90%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. Abbott Laboratories’s payout ratio is 87.60%.

In other news, insider Alejandro D. Wellisch sold 2,153 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total value of $120,266.58. Following the completion of the sale, the insider now directly owns 10,256 shares in the company, valued at approximately $572,900.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Daniel Gesua Sive Salvadori sold 71,157 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $55.00, for a total value of $3,913,635.00. Following the completion of the sale, the insider now owns 144,955 shares of the company’s stock, valued at $7,972,525. The disclosure for this sale can be found here. Over the last three months, insiders sold 501,172 shares of company stock valued at $27,533,150. Corporate insiders own 0.76% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in ABT. Gratus Capital LLC lifted its position in shares of Abbott Laboratories by 0.9% during the 2nd quarter. Gratus Capital LLC now owns 205,067 shares of the healthcare product maker’s stock worth $9,968,000 after buying an additional 1,869 shares in the last quarter. Vantage Investment Advisors LLC lifted its position in shares of Abbott Laboratories by 103.4% during the 2nd quarter. Vantage Investment Advisors LLC now owns 72,161 shares of the healthcare product maker’s stock worth $3,508,000 after buying an additional 36,683 shares in the last quarter. Zurich Insurance Group Ltd FI lifted its position in shares of Abbott Laboratories by 2.5% during the 2nd quarter. Zurich Insurance Group Ltd FI now owns 240,866 shares of the healthcare product maker’s stock worth $11,708,000 after buying an additional 5,790 shares in the last quarter. Amalgamated Bank lifted its position in shares of Abbott Laboratories by 57.6% during the 2nd quarter. Amalgamated Bank now owns 191,206 shares of the healthcare product maker’s stock worth $9,295,000 after buying an additional 69,871 shares in the last quarter. Finally, Sather Financial Group Inc bought a new position in shares of Abbott Laboratories during the 2nd quarter worth approximately $292,000. Institutional investors and hedge funds own 71.15% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/13/abbott-laboratories-target-of-unusually-high-options-trading-abt.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.